Usually a combination of an aromatase inhibitor (or fulvestrant) and a CDK4/6 inhibitor (such as palbociclib, ribociclib, or abemaciclib).
As of early 2026, the European Commission approved inavolisib (Itovebi) for use in combination with palbociclib and fulvestrant for advanced forms of the disease. Download Traitement cancer sein mГ©tastatique pdf
For patients with ESR1 mutations , newer oral selective estrogen receptor degraders (SERDs) like elacestrant are increasingly utilized. HER2-Positive SENORIF 2025-2026 - Institut Curie Usually a combination of an aromatase inhibitor (or
Treatment decisions are primarily driven by the tumor's biological profile, specifically Hormone Receptor (HR) and HER2 status. HR-Positive, HER2-Negative (Luminal) or abemaciclib). As of early 2026
This remains the most common subtype, representing approximately 70–75% of cases.